Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

488.12 -0.25 (-0.05%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,472,298
Open 488.37
Bid (Size) 488.00 (1)
Ask (Size) 495.00 (5)
Prev. Close 488.37
Today's Range 486.20 - 493.28
52wk Range 340.20 - 496.93
Shares Outstanding 259,428,394
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Gene Editing Stocks That Could Grow Your Wealth
Investors looking for gene editing stocks of cutting edge technology firms should consider these biotech stocks. 
Via InvestorPlace
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
CRISPR Therapeutics could start reporting product revenue soon. 
Via The Motley Fool

Performance

YTD
+18.79%
+18.79%
1 Month
+3.05%
+3.05%
3 Month
+24.17%
+24.17%
6 Month
+12.53%
+12.53%
1 Year
+35.97%
+35.97%

More News

Read More
Bull Market and Beyond: 2 Stocks Just Waiting to Soar
Via The Motley Fool
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
Via The Motley Fool
Got $1,000? 2 Incredible Growth Stocks to Buy and Hold Forever
Via The Motley Fool
Forecasting The Future: 13 Analyst Projections For Vertex Pharmaceuticals
Via Benzinga
Check Out What Whales Are Doing With VRTX
Via Benzinga
Why the quality investor may take a look at NASDAQ:VRTX.
Via Chartmill
$1000 Invested In This Stock 15 Years Ago Would Be Worth $14,000 Today
Via Benzinga
The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024
Via InvestorPlace
Healthcare Stocks Continue To Lag The Market-Can Anything Help ?
Via Talk Markets
3 No-Brainer Stocks to Buy in July
Via The Motley Fool
3 Pharma Stocks Already Ushering in the Next Biotech Boom
Via InvestorPlace
Prediction: This Will Be Vertex Pharmaceuticals' New Billion-Dollar Growth Driver (and It's Coming Soon).
Via The Motley Fool
The 3 Best Biotech Stocks to Buy in July 2024
Via InvestorPlace
1 Stock That Increased 10,000% in 33 Years to Buy and Hold Forever
Via The Motley Fool
Did Vertex Pharmaceuticals Just Invent the Next Ozempic?
Via The Motley Fool
Forget Eli Lilly: 3 Biotech Stocks to Buy Instead
Via The Motley Fool
3 Top-Rated Gene Editing Stocks Actually Making Money
Via InvestorPlace
Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Via MarketBeat
Topics ETFs
Exposures COVID-19
Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis
From Vertex Pharmaceuticals Incorporated
Via Business Wire
3 Under-the-Radar Biotech Stocks With Blockbuster Potential
Via InvestorPlace
Vertex to Announce Second Quarter 2024 Financial Results on August 1
From Vertex Pharmaceuticals Incorporated
Via Business Wire
3 Breakout Biotech Stocks on Track to Double by 2032
Via InvestorPlace
Bull Market Buys: 2 Growth Stocks to Own for the Long Run
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.